Biggest changeResults of Operations For the Years Ended December 31, 2023 and 2022 The following table summarizes the results of operations for the periods indicated: For the Years Ended December 31, 2023 2022 Revenues $ 20,481,330 $ 16,418,141 Costs and Expenses Cost of revenues 5,477,032 5,049,701 Research and development 1,407,580 4,009,769 Sales and marketing 4,884,267 3,949,026 General and administrative 13,633,193 16,879,858 Separation expenses 599,832 5,417,043 Depreciation and amortization 74,438 65,554 Operating loss from continuing operations $ (5,595,012 ) $ (18,952,810 ) Comparison of Years Ended December 31, 2023 and 2022 Revenues Revenues for the year ended December 31, 2023 were $20,481,330, which represented an increase of $4,063,189, compared to revenues of $16,418,141 for the year ended December 31, 2022.
Biggest changeStrategic Review and Transaction Related Expenses Strategic review and transaction related expenses consist of legal and professional fees related to a strategic review of the Company’s operations and the acquisition of Kyber. 27 Table of Contents Results of Operations For the Years Ended December 31, 2024 and 2023 The following table summarizes the results of operations for the periods ind icated: For the Years Ended December 31, 2024 2023 (as restated) Revenues $ 20,153,263 $ 21,216,984 Costs and Expenses Cost of revenues 7,334,163 5,477,032 Research and development 1,444,745 1,407,580 Sales and marketing 4,334,289 4,957,833 General and administrative 12,536,940 12,600,208 Separation expenses — 599,832 Litigation settlements and related expenses 669,955 1,032,985 Strategic review and transaction related expenses 756,743 — Depreciation and amortization 63,389 74,438 Operating loss from continuing operations $ (6,986,961 ) $ (4,932,924 ) Comparison of Years Ended December 31, 2024 and 2023 Revenues Revenues for the for the year ended December 31, 2024, were $20,153,263, which represented a decrease of $1,063,721 compared to revenues of $21,216,984 for the year ended December 31, 2023.
As more fully described below, management believes that providing Adjusted EBITDA, together with a reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons between the Company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation.
As more fully described below, management believes that providing Adjusted EBITDA, together with a reconciliation of net (loss) income to Adjusted EBITDA, helps investors make comparisons between the Company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation.
However, Adjusted EBITDA is not intended as a substitute for comparisons based on net loss. In making any comparisons to other companies, investors should be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding U.S.
However, Adjusted EBITDA is not intended as a substitute for comparisons based on net (loss) income. In making any comparisons to other companies, investors should be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding U.S.
Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” the Company is not required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.
Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” the Company is not required to, among other things, (i) provide an auditor’s attestation report on its system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.
Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board of Directors resigned. In connection with the resignation, the Company entered into a separation agreement providing for, among other things, (i) salary continuation for twelve months and (ii) accelerated vesting of 106,656 unvested restricted shares of the Company common stock.
Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board resigned. In connection with the resignation, the Company entered into a separation agreement providing for, among other things, (i) salary continuation for twelve months and (ii) accelerated vesting of 106,656 unvested restricted shares of the Company common stock.
Sales and Marketing Sales and marketing expense is primarily salaries and related expenses, including commissions, for our sales, marketing and product management staff. Marketing program costs are also recorded as sales and marketing expense including advertising, market research and events (such as trade shows, corporate communications, brand building, etc.).
Sales and Marketing Sales and marketing expense is primarily salaries and related expenses, including commissions, for sales, marketing and product management staff. Marketing program costs are also recorded as sales and marketing expense including advertising, market research and events (such as trade shows, corporate communications, brand building, etc.).
Stock-based compensation expense includes certain separation expenses related to the vesting of stock options. Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board of Directors resigned.
Stock-based compensation expense includes certain separation expenses related to the vesting of stock options. Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board resigned.
GAAP. Management encourages investors and others to review the Company’s financial information in its entirety, not to rely on any single financial measure to evaluate the business and to view non-GAAP financial measures in conjunction with the most directly comparable U.S. GAAP financial measures. The following table reconciles the specific items excluded from U.S.
Management encourages investors and others to review the Company’s financial information in its entirety, not to rely on any single financial measure to evaluate the business and to view non-GAAP financial measures in conjunction with the most directly comparable U.S. GAAP financial measures. T he following table reconciles the specific items excluded from U.S.
Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the healthcare and life sciences industries. 24 Table of Contents The business combination with Helix was accounted for as a reverse acquisition using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”), with the Company deemed the accounting acquirer for financial reporting purposes.
Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the healthcare and life sciences and financial services industries. 25 Table of Contents The business combination with Helix was accounted for as a reverse acquisition using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”), with the Company deemed the accounting acquirer for financial reporting purposes.
Interest expense is associated with the convertible notes entered into on September 1, 2021 in the amount of $24,000,000 (the “Notes”). The Notes are due on September 1, 202 5, and accrue interest at an annual rate of 3.5%.
Interest expense is associated with the convertible notes entered into on September 1, 2021 in the amount of $24,000,000 (the “Notes”). The Notes are due on September 1, 2025, and accrue interest at an annual rate of 3.5%.
The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. 31 Table of Contents On an on-going basis, the Company evaluates its estimates, including those related to revenues, stock-based compensation, income taxes, contingencies and litigation.
The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, including those related to revenues, stock-based compensation, income taxes, contingencies and litigation.
The Company plans to continue investing in marketing and sales by expanding selling and marketing staff, building brand awareness, attracting new clients and sponsoring additional marketing events. The timing of these marketing events may affect marketing costs in any particular quarter.
The Company plans to continue investing in marketing and sales by expanding selling and marketing staff, building brand awareness, attracting new clients and sponsoring additional marketing events. The timing of these marketing events may affect marketing costs in any particular p eriod .
GAAP measures provided by each company under applicable SEC rules. The following is an explanation of the items excluded from Adjusted EBITDA but included in net loss from continuing operations: • Depreciation and Amortization.
GAAP measures provided by each company under applicable SEC rules. 29 Table of Contents The following is an explanation of the items excluded from Adjusted EBITDA but included in net loss from continuing operations: • Depreciation and Amortization.
The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Investors should note that interest expense associated with the Notes will recur in future periods. • Investment Income. Investment income is associated with the level of marketable debt securities and other interest-bearing accounts in which we invest. Interest and investment income can vary over time due to changes in interest rates and level of investments.
Investors should note that interest expense associated with the Notes will recur in future periods. • Interest and Investment Income. Interest and Investment income is associated with the level of marketable debt securities and other interest-bearing accounts in which the Company invests. Interest and investment income can vary over time due to changes in interest rates and level of investments.
Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, including our plans, objectives, expectations, intentions and those set forth under “Cautionary Statement About Forward-Looking Statements.” Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Item 1A.
The following discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, including plans, objectives, expectations, intentions and those set forth under “Cautionary Statement for Forward-Looking Information.” Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Item 1A.
Management’s Discussion and Analysis of Financial Condition and Results of Operations Cautionary Statement for Forward-Looking Information The following discussion of our financial condition and results of operations for the fiscal years ended December 31, 2023 and 2022 should be read in conjunction with our consolidated financial statements and the notes to those statements that are included elsewhere in this Annual Report on Form 10-K.
Management’s Discussion and Analysis of Financial Condition and Results of Operations Cautionary Statement for Forward-Looking Information The following discussion of the Company’s financial condition and results of operations for the years ended December 31, 2024 and 2023 should be read in conjunction with the consolidated financial statements and the notes to those statements that are included elsewhere in this Annual Report on Form 10-K.
Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future. 28 Table of Contents • Interest Expense.
Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future. • Interest Expense.
General and Administrative Expenses 25 Table of Contents General and administrative expenses include salaries, benefits and other costs of departments serving administrative functions, such as executives, finance and accounting and human resources.
General and Administrative Expenses General and administrative expenses include salaries, benefits and other costs of departments serving administrative functions, such as executives, finance and accounting and human resources.
Non-GAAP Financial Measures In this Annu al Report on Form 10-K the Company has provided a non-GAAP measure, which is defined as financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“ U.S. GAAP”) .
Non-GAAP Financial Measures In this Annual Report on Form 10-K the Company has provided a non-GAAP measure, which is defined as financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Investors should note that interest income will recur in future periods. • Other Items. The Company engages in other activities and transactions that can impact net income (loss).
Investors should note that interest income will recur in future periods. 30 Table of Contents • Other Items. The Company engages in other activities and transactions that can impact net income (loss).
Under ASU 2023-09, for each annual period presented, public entities are required to (1) disclose specific categories in the tabular rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold.
ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid and other disclosures. Under ASU 2023-09, for each annual period presented, public entities are required to (1) disclose specific categories in the tabular rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold.
Cost of Revenues Cost of revenues is generated from direct costs associated with the delivery of our products and services to our customers. The cost of revenues relates primarily to labor costs, information licensing, hosting and infrastructure costs and client service team costs. We record the cost of direct fulfillment as cost of revenues.
Cost of Revenues Cost of revenues is generated from direct costs associated with the delivery of the Company’s products and services to its customers. The cost of revenues relates primarily to labor costs, information licensing, hosting and infrastructure costs and client service team costs.
Helix provided software and analytics solutions to state governments and licensed operators within the cannabis industry, primarily through its subsidiary, Bio-Tech Medical Software, Inc. (“BioTrack”), until its sale of BioTrack in 2023.
Helix provided software and analytics solutions to state governments and licensed operators within the cannabis industry, primarily through its subsidiary, Bio-Tech Medical Software, Inc. (“BioTrack”), until its sale of BioTrack in 2023. On February 10, 2023, Helix completed the sale of 100% of the outstanding capital stock of BioTrack.
In addition, general and administrative expense includes non-personnel costs, such as professional fees, legal fees, accounting and finance advisory fees and other supporting corporate expenses not allocated to cost of revenues, product and development or sales and marketing. Depreciation and Amortization Expenses Depreciation and amortization relate to long lived assets used in our business.
In addition, general and administrative expense includes non-personnel costs, such as professional fees, legal fees, accounting and finance advisory fees and other supporting corporate expenses not allocated to cost of revenues, product and development or sales and marketing.
ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024 and can be applied on a prospective basis with an option to apply the standard retrospectively. Early adoption is permitted.
ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024 and can be applied on a prospective basis with an option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements and related disclosures.
These exemptions will apply until the fifth anniversary of the business combination or until we no longer meet the requirements for being an “emerging growth company,” whichever occurs first .
These exemptions will apply until the fifth anniversary of the business combination with Helix or until the Company no longer meets the requirements for being an “emerging growth company,” whichever occ urs first.
In the periods reported, these other items included (i) change in fair value of warrant liability relating to warrants assumed in the acquisition of Helix; (ii) gain on sale of investment relating to the sale of a minority equity interest; (iii) gain on debt redemption which relates to a gain on the early retirement of a portion of the convertible notes (for further discussion, refer to “Note 10 – Warrant Liability” and “Note 12 – Convertible Notes” in the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K) and (iv) litigation related expenses.
In the periods reported, these other items included (i) change in fair value of warrant liability relating to warrants assumed in the acquisition of Helix; (ii) gain on sale of investment relating to the sale of a minority equity interest; (iii) gain on debt redemption which relates to a gain on the early retirement of a portion of the Notes (for further discussion, refer to “Note 12 – Warrant Liability” and “Note 13 – Convertible Notes” to the financial statements) and (iv) gain on bargain purchase (for further discussion refer to Note 5 - Acquisition).
The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements and related disclosures The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on our financial statements. JOBS Act On April 5, 2012, the JOBS Act was signed into law.
The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. 35 Table of Contents JOBS Act On April 5, 2012, the JOBS Act was signed into law.
Severance expenses for the year ended December 31, 2023 includes $250,000 related to the salary continuation. Managements excludes these other items from Adjusted EBITDA because management believes these costs are not recurring and not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance.
Managements excludes these other items from Adjusted EBITDA because management believes these costs are not recurring and not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance.
(the “Company,” “Forian,” “we” or “us”) was incorporated in Delaware on October 15, 2020 as a wholly owned subsidiary of Medical Outcomes Research Analytics, LLC (“MOR”) for the purpose of effecting the business combination with Helix Technologie s, Inc. (“Helix”).
(the “Company” or “Forian”) was incorporated in Delaware on October 15, 2020 as a wholly owned subsidiary of Forian LLC (f/k/a Medical Outcomes Research Analytics, LLC) (“MOR”) for the purpose of effecting the business combination with Helix Technologies, Inc. (“Helix”).
Critical Accounting Policies and Estimates Management’s discussion and analysis of the Company’s financial condition and results of operations are based upon the Company’s Consolidated Financial Statements that have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).
Critical Accounting Estimates Management’s discussion and analysis of the Company’s financial condition and results of operations are based upon the Company’s Consolidated Financial Statements that have been prepared in accordance with US GAAP.
Research and Development Research and development expenses consist primarily of employee-related expenses, subcontractor and third-party consulting fees and hosted infrastructure costs. The Company continues to focus research and development efforts on adding new features and applications to our product offerings.
The Company continues to evaluate any impact on customer performance commitments and the availability of alternate sources of comparable data. Research and Development Research and development expenses consist primarily of employee-related expenses, subcontractor and third-party consulting fees and hosted infrastructure costs. The Company continues to focus research and development efforts on adding new features and applications to its product offerings.
Management excludes the income tax expense from Adjusted EBITDA (i) because management believes that the income tax expense is not directly attributable to the underlying performance of business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes.
Management excludes the income tax (benefit) expense from Adjusted EBITDA (i) because management believes that the income tax (benefit) expense is not directly attributable to the underlying performance of business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes. 31 Table of Contents Limitations on the use of non-GAAP financial measures There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with U.S.
Judgement is also necessary to assess revenue recognized under contingent revenue arrangements. Share-Based Payments Under the fair value recognition provision, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period.
Share-Based Payments Under the fair value recognition provision, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period. The Company makes certain assumptions in order to value and expense its various share-based payment awards.
We make certain assumptions in order to value and expense our various share-based payment awards. Income Taxes The Company utilizes judgement and estimates in assessing the need for the valuation allowance related to deferred tax assets, including net operating loss carry-forwards.
Income Taxes The Company utilizes judgement and estimates in assessing the need for the valuation allowance related to deferred tax assets, including net operating loss carry-forwards.
Risk Factors” and elsewhere in this Annual Report on Form 10-K. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Overview Forian Inc.
Risk Factors” and elsewhere in this Annual Report on Form 10-K. The Company uses words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. As discussed in “Note 20 - Restatement of Previously Issued Financial Statements” in “Item 8.
The increase is primarily due to increased sales of information products to new and existing customers in the healthcare industry.
The decrease is primarily due to increased sales of information products to new and existing customers in the healthcare industry offset by the impact of attrition of a larger customer.
The Company evaluated the divestitures of the Helix Business in accordance with ASC 205-20 and determined that transactions in aggregate represented a strategic shift that had a major impact on the Company.
Further, the Company recorded a gain on the sale of discontinued operations, net of tax during the year ended December 31, 2023. The Company evaluated the divestitures of the Helix Business in accordance with ASC 205-20 and determined that transactions in aggregate represented a strategic shift that had a major impact on the Company.
On July 21, 2023, the Company sold a minority equity interest in a customer for cash proceeds of $5,805,858 and future contingent earnout payments aggregating up to $3,600,000 in 2025 and 2026. These transactions have provided additional cash and liquidity to the Company.
On February 10, 2023, the Company sold BioTrack for $30,000,000 consisting of $20,000,000 in cash at closing and twelve unconditional monthly payments aggregating $10,000,000 thereafter. On July 21, 2023, the Company sold a minority equity interest in a customer for cash proceeds of $5,805,858 and future contingent earnout payments aggregating up to $3,600,000 in 2025 and 2026.
Net Cash Used in Financing Activities Net cash used in financing activities of $ 4,601,518 for the year ended December 31, 2023 increased by $ 4,500,990 compared to cash used in financing activities of $ 100,528 for the year ended December 31, 2022 .
Net Cash Used In Financing Activities Net cash used in financing activities of $ 19,023,897 for the year ended December 31, 2024 increased by $ 14,422,379 compared to cash used in financing activities of $ 4,601,518 for the year ended December 31, 2023 .
The decrease is primarily due to lower personnel costs, consulting and insurance costs . Separation Expenses Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board of Directors resigned.
Separation Expenses Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board of Directors of the Company (the “Board”) resigned.
As a result of these transactions, Helix has no remaining active operations and the Company no longer provides products or services to the cannabis industry. The results of the Helix Businesses are presented as discontinued operations in the Consolidated Statements of Operations and, as such, have been excluded from continuing operations.
These businesses are referred to collectively as the “Helix Businesses.” As a result of these transactions, Helix has no remaining active operations and the Company no longer provides products or services to the cannabis industry.
Separation expenses for the year ended December 31, 2023 include $250,000 related to the salary continuation and $349,832 related to the accelerated vesting of stock. On March 2, 2022, the Company and two advisors mutually agreed not to renew special advisor agreements between the advisors and the Company.
Separation expenses for the year ended December 31, 2023 include $250,000 related to the salary continuation and $349,832 related to the accelerated vesting of stock.
The decrease is due to lower personnel, subcontracted labor and infrastructure costs related to new product development, which resulted from the Company’s shift in focus to the healthcare analytics market. 26 Table of Contents Sales and Marketing Sales and marketing expenses for the year ended December 31, 2023 were $ 4,884,267 , which represented an increase of $ 935,241 compared to total sales and marketing expenses of $ 3,949,026 for the year ended December 31, 2022 .
The decrease is due to is due to lower personnel, subcontracted labor and infrastructure costs related to new product development, which resulted from the Company’s shift in focus to the healthcare analytics market. 44 Table of Contents Sales and Marketing Sales and marketing expenses for the nine months ended September 30, 2024 were $3,029,783, which represented a decrease of $776,365 compared to total sales and marketing expenses of $3,806,148 for the nine months ended September 30, 2023.
On February 10, 2023, Helix completed the sale of 100% of the outstanding capital stock of BioTrack; on March 3, 2022, Helix completed the sale of the assets of its security monitoring business; and on October 31, 2022, Helix completed the sale of 100% of the outstanding membership interest of its Engeni LLC subsidiary (these businesses are referred to collectively as the “Helix Businesses”).
On March 3, 2022, Helix completed the sale of the assets of its security monitoring business. On October 31, 2022, Helix completed the sale of 100% of the outstanding membership interest of its Engeni LLC subsidiary.
In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net loss, as well as trends in those items contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations. 27 Table of Contents Management believes that the presentation of Adjusted EBITDA is useful to investors in their analysis of the Company’s results for reasons similar to those believed by management, Additionally, Adjusted EBITDA helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions.
In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net loss, as well as trends in those items contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Management compensates for these limitations by analyzing current and future results on a U.S. GAAP basis as well as a non-GAAP basis and also by providing U.S. GAAP measures in the Company’s public disclosures. 29 Table of Contents Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S.
GAAP measures in the Company’s public disclosures. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP.
Research and Development Research and development expenses for the year ended December 31, 2023 were $ 1,407,580 , which represented a decrease of $ 2,602,189 compared to total research and development expenses of $ 4,009,769 for the year ended December 31, 2022 .
Research and Development Research and development expenses for the year ended December 31, 2024 , were $1,444,745 , which represented an increase of $37,165 compared to total research and development expenses of $1,407,580 for the year ended December 31, 2023 .
Net Cash Provided By (Used in) Investing Activities Net cash provided by investing activities of $ 7,119,943 increased by $ 11,917,210 for the year ended December 31, 2023 compared to cash used in investing activities of $ 4,797,267 for the year ended December 31, 2022 .
Net Cash Provided By Investing Activities Net cash provided by investing activities of $ 17,288,745 increased by $ 10,168,802 for the year ended December 31, 2024 compared to cash provided by investing activities of $ 7,119,943 for the year ended December 31, 2023 .
In addition, the Company records normal course of business severance expenses in the operating expense line item related to our employees’ activities. • Income tax expense.
In addition, the Company records normal course of business severance expenses in the operating expense line item related to its employees’ activities. • Litigation related expenses. Management excludes litigation expenses that are extraordinary in nature and are unrelated to the Company’s day-to-day business operations.
Accounting for discontinued operations and the related gain on sale of discontinued operations requires us to make estimates and judgements regarding the allocation of costs and net asset values to discontinued operations. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13— Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments .
Accounting for discontinued operations and the related gain on sale of discontinued operations required the Company to make estimates and judgements regarding the allocation of costs and net asset values to discontinued operations. Recent Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update No. 2023-09 , Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ ASU 2023-09”).
The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are adjusted to calculate non-GAAP financial measures.
GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon reported financial results.
Financial Operations Overview The following discussion sets forth certain components of our statements of operations as well as factors that impact those items. Revenues Revenues are derived from licensing fees for the Company’s proprietary information products. The Company recognizes revenues from information products as performance obligations under customer contracts are satisfied.
Revenues Revenues are derived from fees for the Company’s proprietary information products and services. The Company recognizes revenues from information products as performance obligations under customer contracts are satisfied.
Discontinued Operations In accordance with ASC 205-20 Discontinued Operations, the results of the Helix Businesses are presented as discontinued operations in the Consolidated Statements of Operations and, as such, have been excluded from continuing operations.
The results of the Helix Businesses are presented as discontinued operations in the Consolidated Statements of Operations and, as such, have been excluded from continuing operations. On October 31, 2024, the Company entered into a Membership Interest Assignment Agreement, by and among Cowen Inc.
GAAP metrics in the calculation of Adjusted EBITDA for the periods shown below: For the Years Ended December 31, 2023 2022 Revenue $ 20,481,330 $ 16,418,141 Net Income (loss) from continuing operations 1,733,430 (19,191,990 ) Depreciation and amortization 74,438 65,554 Stock based compensation expense 6,573,969 11,920,575 Change in fair value of warrant liability (3,984 ) (364,687 ) Interest and investment income (2,327,974 ) (266,213 ) Interest expense 834,785 846,100 Gain on sale of investment (5,805,858 ) — Gain on debt redemption (111,151 ) — Severance expense 250,000 — Litigation related expenses 1,032,985 258,872 Income tax expense 85,740 23,980 Adjusted EBITDA - continuing operations $ 2,336,380 $ (6,707,809 ) Comparison of Years Ended December 31, 2023 and 2022 Adjusted EBITDA - continuing operations Adjusted EBITDA for the year ended December 31, 2023 was $2,336,380 compared to a loss of $6,707,809 for the years ended December 31, 2022 , an increase of $9,044,189 .
GAAP metrics in the calculation of Adjusted EBITDA for the periods shown below: For the Years Ended December 31, 2024 2023 (as restated) Revenue $ 20,153,263 $ 21,216,984 Net (loss) income from continuing operations (3,771,070 ) 2,395,518 Depreciation and amortization 63,389 74,438 Stock based compensation expense 6,528,397 6,573,969 Change in fair value of warrant liability (563 ) (3,984 ) Interest and investment income (2,422,261 ) (2,327,974 ) Interest expense 708,933 834,785 Gain on sale of investment (80,694 ) (5,805,858 ) Gain on debt redemption (283,059 ) (111,151 ) Gain on bargain purchase (1,204,830 ) — Severance expense — 250,000 Litigation related expenses 669,955 1,032,985 Strategic review and transaction related expenses 756,743 — Contract termination impacts (542,389 ) — Income tax expense 66,583 85,740 Adjusted EBITDA - continuing operations $ 489,134 $ 2,998,468 Comparison of the Years Ended December 31, 2024 and 2023 Adjusted EBITDA - continuing operations Adjusted EBITDA for the year ended December 31, 2024, was $489,134 compared to $2,998,468 for the year ended December 31, 2023, a decrease of $2,509,334.
The Company believes the following critical accounting policies and estimates used in the preparation of its Consolidated Financial Statements affect its more significant judgments and estimates. Revenue The Company utilizes judgement to determine whether performance obligations in a contract are distinct and whether they are delivered at a point in time or over time.
Revenue The Company utilizes judgement to determine whether performance obligations in a contract are distinct and whether they are delivered at a point in time or over time. Judgement is also necessary to assess revenue recognized under variable revenue arrangements.
The increase is due to higher salaries, commissions and expenses related to scaling the Company’s products. General and Administrative General and administrative expenses for the year ended December 31, 2023 were $ 13,633,193 , which represented a decrease of $ 3,246,665 compared to general and administrative expenses of $ 16,879,858 for the year ended December 31, 2022 .
The decrease is due to lower salaries and expenses related to scaling the Company’s products. 37 Table of Contents General and Administrative General and administrative expenses for the three months ended March 31, 2024 were $3,283,489, which represented a decrease of $271,986 compared to general and administrative expenses of $3,555,475 for the three months ended March 31, 2023.
The Company expects to continue to fund its operations and potential future acquisitions through a combination of cash flow generated from operating activities, available cash and marketable securities, debt f inancing and /or additional equity issuances. 30 Table of Contents Cash Flows The following table summarizes selected information about sources and uses of cash and cash equivalents for the periods presented: For the Years Ended December 31, 2023 2022 Net cash provided by (used in) operating activities - continuing operations $ 787,893 $ (6,071,014 ) Net cash provided by (used in) investing activities - continuing operations 7,119,943 (4,797,267 ) Net cash used in financing activities - continuing operations (4,601,518 ) (100,528 ) Net increase in cash and cash equivalents - continuing operations $ 3,306,318 $ (10,968,809 ) Net Cash Provided By (Used in) Operating Activities Net cash provided by operating activities increased to $ 787,893 for the year ended December 31, 2023 compared to cash used in operating activities of $ 6,071,014 for the year ended December 31, 2022 .
Cash Flows The following table summarizes selected information about sources and uses of cash and cash equivalents for the periods presented: For the Years Ended December 31, 2024 2023 (as restated) Net cash provided by operating activities - continuing operations $ 282,827 $ 787,893 Net cash provided by investing activities - continuing operations 17,288,745 7,119,943 Net cash used in financing activities - continuing operations (19,023,897 ) (4,601,518 ) Net (decrease) increase in cash and cash equivalents - continuing operations $ (1,452,325 ) $ 3,306,318 Net Cash Provided By Operating Activities Net cash provided by operating activities of $282,827 decreased by $505,066 for the year ended December 31, 2024 compared to cash provided by operating activities of $787,893 for the year ended December 31, 2023.
Cost of Revenues Cost of revenues for the year ended December 31, 2023 was $ 5,477,032 , which represented an increase of $ 427,331 compared to total cost of revenues of $ 5,049,701 for the year ended December 31, 2022 .
Cost of Revenues Cost of revenues for the year ended December 31, 2024 , was $7,334,163 , which represented an increase of $1,857,131 compared to cost of revenues of $5,477,032 for the year ended December 31, 2023 . Cost of revenues increased primarily due to the impact of the Kyber acquisition and higher information licensing expenses.
Cost of revenues increased at a lower rate than revenue, as many data infrastructure costs are fixed or semi-variable in nature. As a result, gross profit as a percentage of revenues increased to 73% for the for the year ended December 31, 2023 , compared to 69% for the same period in 2022.
As a result, gross profit as a percentage of revenues decreased to 64% for the year ended December 31, 2024 , compared to 74% for the same period in 2023 .
As of December 31, 2023 , the Company’s balance of cash and marketable securities aggregated $48,339,575 and outstanding principal and accrued interest on the Notes, due September 1, 2025, aggregated $24,870,181 .
These transactions have provided additional cash and liquidity to the Company. During 2024, the Company redeemed $18,881,466 in outstanding principal and interest on its Notes. As of December 31, 2024 , the Company’s balance of cash and marketable securities aggregated $35,082,749 and outstanding principal and accrued interest on the Notes, due September 1, 2025, aggregated $6,697,649 .
This is primarily the result of an increase in net purchases of marketable securities of $144,077,731 , offset by an increase in cash received from the sale of discontinued operations of $24,413,595 , the sale of marketable securities of $121,053,714 , and proceeds from the sale of investment of $5,805,858.
This is primarily the result of changes in the impact of cash from acquisitions, disposition of discontinued operations, sale of investment and changes in net additions to marketable securities.